Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Jun 25. pii: e8741. doi: 10.15252/emmm.201708741. [Epub ahead of print]

2.

Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients.

Rigamonti A, Imbesi F, Silvani A, Gaviani P, Agostoni E, Porcu L, De Simone I, Torri V, Salmaggi A.

J Neurol Sci. 2018 Jul 15;390:14-19. doi: 10.1016/j.jns.2018.04.004. Epub 2018 Apr 5.

PMID:
29801876
3.

Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population.

Genovesi S, Slaviero G, Porcu L, Casu G, Bertoli S, Sagone A, Pieruzzi F, Rovaris G, Buskermolen M, Danna P, Montoli A, Oreglia J, Contaldo G, Mazzone P.

Int J Cardiol. 2018 Jul 1;262:38-42. doi: 10.1016/j.ijcard.2018.03.083.

PMID:
29706393
4.

Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S.

Breast Care (Basel). 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12.

PMID:
29456471
5.

Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.

Terrone G, Pauletti A, Salamone A, Rizzi M, Villa BR, Porcu L, Sheehan MJ, Guilmette E, Butler CR, Piro JR, Samad TA, Vezzani A.

Epilepsia. 2018 Jan;59(1):79-91. doi: 10.1111/epi.13950. Epub 2017 Nov 24.

PMID:
29171003
6.

Autologous fat tissue grafting improves pulmonary healing after laser metastasectomy.

Furia S, Cadenelli P, Andriani F, Scanagatta P, Duranti L, Spano A, Galeone C, Porcu L, Pastorino U.

Eur J Surg Oncol. 2017 Dec;43(12):2315-2323. doi: 10.1016/j.ejso.2017.09.020. Epub 2017 Oct 16.

PMID:
29111365
7.

The Prison of Shame: Finding a Passage Through Dreams.

Porcu L.

Psychoanal Rev. 2017 Oct;104(5):595-628. doi: 10.1521/prev.2017.104.5.595.

PMID:
29022847
8.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

9.

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G.

Drugs R D. 2017 Sep;17(3):461-467. doi: 10.1007/s40268-017-0203-y.

10.

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Erba E, Romano M, Gobbi M, Zucchetti M, Ferrari M, Matteo C, Panini N, Colmegna B, Caratti G, Porcu L, Fruscio R, Perlangeli MV, Mezzanzanica D, Lorusso D, Raspagliesi F, D'Incalci M.

Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.

PMID:
28782526
11.

Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.

Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M.

J Clin Invest. 2017 Jun 1;127(6):2118-2132. doi: 10.1172/JCI92001. Epub 2017 May 15.

12.

Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.

Ballerini A, Moro F, Nerini IF, Marzo CM, Di Clemente A, Ferrari M, D'Incalci M, Biondi A, Colombini A, Conter V, Porcu L, Cervo L, Rizzari C, Zucchetti M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1267-1271. doi: 10.1007/s00280-017-3307-8. Epub 2017 Apr 19.

PMID:
28424964
13.

Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis.

Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Contaldo G, Stella A, Pozzi C, Ondei P, Minoretti C, Gallieni M, Pontoriero G, Conte F, Torri V, Bertoli S, Vincenti A.

Blood Purif. 2017;44(1):77-88. doi: 10.1159/000464347. Epub 2017 Apr 1.

14.

Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.

Lorusso V, Cinieri S, Latorre A, Porcu L, Del Mastro L, Puglisi F, Barni S.

Future Oncol. 2017 May;13(11):971-978. doi: 10.2217/fon-2016-0530. Epub 2017 Feb 24.

PMID:
28326833
15.

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G.

Oncology. 2017;92(5):269-275. doi: 10.1159/000455970. Epub 2017 Feb 17.

PMID:
28208153
16.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

17.

Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.

Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, de Braud F, Di Cosimo S.

Breast Cancer. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6. Epub 2017 Jan 5.

PMID:
28058615
18.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
19.

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G.

Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485.

20.

Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, Petrelli F, Scartozzi M, Torri V, Barni S.

Clin Colorectal Cancer. 2017 Jun;16(2):e61-e72. doi: 10.1016/j.clcc.2016.08.006. Epub 2016 Aug 31. Review.

21.

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G.

Crit Rev Oncol Hematol. 2016 Aug;104:9-20. doi: 10.1016/j.critrevonc.2016.05.004. Epub 2016 May 13.

PMID:
27286698
22.

Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy.

Pascente R, Frigerio F, Rizzi M, Porcu L, Boido M, Davids J, Zaben M, Tolomeo D, Filibian M, Gray WP, Vezzani A, Ravizza T.

Neurobiol Dis. 2016 Sep;93:146-55. doi: 10.1016/j.nbd.2016.05.001. Epub 2016 May 10.

PMID:
27173096
23.

Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist.

Corli O, Martoni AA, Porcu L, Roberto A, Pinto C, Torri V, Guglieri I, Zagonel V; EPIDEMIOLOGY STUDY OF PAIN IN ONCOLOGY (ESOPO) GROUP.

Eur J Intern Med. 2016 Sep;33:e18-9. doi: 10.1016/j.ejim.2016.04.019. Epub 2016 May 5. No abstract available.

PMID:
27155804
24.

Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.

Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, Gronchi A, Picci P.

Spine (Phila Pa 1976). 2016 Jun;41(12):1049-57. doi: 10.1097/BRS.0000000000001604.

PMID:
27054448
25.

Multimodal study of default-mode network integrity in disorders of consciousness.

Rosazza C, Andronache A, Sattin D, Bruzzone MG, Marotta G, Nigri A, Ferraro S, Sebastiano DR, Porcu L, Bersano A, Benti R, Leonardi M, D'Incerti L, Minati L; Coma Research Centre (CRC) - Besta Institute.

Ann Neurol. 2016 Mar 11. doi: 10.1002/ana.24634. [Epub ahead of print]

PMID:
26970235
26.

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, Dell'Anna T, Fruscio R, Damia G.

Oncotarget. 2017 Jan 31;8(5):7441-7451. doi: 10.18632/oncotarget.7465.

27.

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.

Belli C, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M.

Cancer Chemother Pharmacol. 2016 Mar;77(3):477-84. doi: 10.1007/s00280-015-2932-3. Epub 2015 Dec 14.

PMID:
26666646
28.

In Response.

Billè A, Porcu L.

J Thorac Oncol. 2015 Sep;10(9):e93-e94. doi: 10.1097/JTO.0000000000000614. No abstract available.

29.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
30.

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.

Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F, Procopio G.

Ther Adv Urol. 2015 Apr;7(2):59-68. doi: 10.1177/1756287215571809.

31.

Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population.

Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Stella A, Pozzi C, Ondei P, Minoretti C, Gallieni M, Pontoriero G, Conte F, Torri V, Vincenti A.

Int J Cardiol. 2015;186:170-7. doi: 10.1016/j.ijcard.2015.03.178. Epub 2015 Mar 17.

PMID:
25819895
32.

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.

Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S.

Clin Transl Oncol. 2015 Jul;17(7):530-8. doi: 10.1007/s12094-015-1274-2. Epub 2015 Jan 21.

PMID:
25604128
33.

Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?

Pugliese DB, Bruzzesi G, Montaldo C, Porcu L, Landi M, Mastinu A, Torri V, Licitra L, Locati LD.

J Oral Pathol Med. 2015 Oct;44(9):728-33. doi: 10.1111/jop.12291. Epub 2014 Nov 17.

PMID:
25401955
34.

Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.

Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, Gori S, La Verde N.

Tumori. 2014 Jul-Aug;100(4):426-31. doi: 10.1700/1636.17902.

PMID:
25296592
35.

Thulium laser versus staplers for anatomic pulmonary resections with incomplete fissures: negative results of a randomized trial.

Scanagatta P, Furia S, Billè A, Duranti L, Girelli L, Tavecchio LD, Leo F, Giovannetti R, Pelosi G, Porcu L, Pastorino U.

Tumori. 2014 May-Jun;100(3):259-64. doi: 10.1700/1578.17196.

PMID:
25076235
36.

Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.

Grassi P, Verzoni E, Porcu L, Testa I, Iacovelli R, Torri V, Braud Fd, Procopio G.

Future Oncol. 2014 Jun;10(8):1361-72. doi: 10.2217/fon.14.69.

PMID:
25052747
37.

Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.

Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, DE Braud F, Procopio G.

Anticancer Res. 2014 May;34(5):2395-8.

PMID:
24778049
38.

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.

Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V.

Lung Cancer. 2014 Jul;85(1):74-80. doi: 10.1016/j.lungcan.2014.03.010. Epub 2014 Mar 16.

PMID:
24746176
39.

Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.

Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB, Garofalo G, Bedini AV, Garassino M, Porcu L, Torri V, Pastorino U.

J Thorac Oncol. 2014 Mar;9(3):390-6. doi: 10.1097/JTO.0000000000000064.

40.

Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.

Di Cosimo S, Serpico D, Porcu L, Molino L, Fanetti G, Torri V, de Braud F.

Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174. doi: 10.1016/j.clon.2013.11.028. Epub 2013 Dec 22. No abstract available.

PMID:
24368057
41.

The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.

Rossi A, Torri V, Garassino MC, Porcu L, Galetta D.

Cancer Treat Rev. 2014 May;40(4):485-94. doi: 10.1016/j.ctrv.2013.09.012. Epub 2013 Sep 25. Review.

PMID:
24112813
42.

ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G.

Am J Cancer Res. 2013 Apr 3;3(2):221-9. Print 2013.

43.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.

44.

Pure epileptic headache and related manifestations: a video-EEG report and discussion of terminology.

Cianchetti C, Pruna D, Porcu L, Peltz MT, Ledda MG.

Epileptic Disord. 2013 Mar;15(1):84-92. doi: 10.1684/epd.2013.0552.

45.

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F.

Br J Cancer. 2012 Oct 9;107(8):1227-32. doi: 10.1038/bjc.2012.327. Epub 2012 Sep 11.

46.

Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M, di Giandomenico S, D'Incalci M.

Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13.

PMID:
22897840
47.

The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.

Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, Porcu L, Bussani C, D'Incalci M, Erba E, Romano M, Cattoretti G, Katsaros D, Koff A, Luzzatto L.

Clin Cancer Res. 2012 Aug 15;18(16):4313-24. Epub 2012 Jun 25.

48.

DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.

Caiola E, Porcu L, Fruscio R, Giuliani D, Milani R, Torri V, Broggini M, Marabese M.

Pharmacogenomics J. 2013 Apr;13(2):159-72. doi: 10.1038/tpj.2011.50. Epub 2011 Dec 13.

PMID:
22158331
49.

Determination of famoxadone, fenamidone, fenhexamid and iprodione residues in greenhouse tomatoes.

Angioni A, Porcu L, Dedola F.

Pest Manag Sci. 2012 Apr;68(4):543-7. doi: 10.1002/ps.2287. Epub 2011 Nov 18.

PMID:
22102420
50.

LC/DAD/ESI/MS method for the determination of imidacloprid, thiacloprid, and spinosad in olives and olive oil after field treatment.

Angioni A, Porcu L, Pirisi F.

J Agric Food Chem. 2011 Oct 26;59(20):11359-66. doi: 10.1021/jf2028363. Epub 2011 Sep 30.

PMID:
21942716

Supplemental Content

Support Center